Review of cancer related surrogate outcomes used for Pharmaceutical Benefits Advisory Committee (PBAC) decision making

Page last updated: 8 September 2023

Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support registration and subsidy of new medicines. At the PBAC’s request, the Department contracted Monash University to develop a report on the use of surrogate outcome measures in PBAC submissions for cancer medicines.

The PBAC considered the report in July 2023. The report and the PBAC Minutes for this item are now available on the Review of cancer related surrogate outcomes used for PBAC decision making webpage.